Original articles / Online first

Short- and long-term outcomes of mechanical thrombectomy in acute ischemic stroke patients with chronic kidney disease

Katarzyna Sawczyńska, Paweł Wrona, Dominik Wróbel, Kaja Zdrojewska, Paulina Sarba, Mateusz Giełczyński, Ewa Włodarczyk, Tadeusz Popiela, Agnieszka Słowik, Marcin Krzanowski
Published online: July 10, 2024

Abstract

Introduction: Chronic kidney disease (CKD) is a risk factor of acute ischemic stroke (AIS). Outcomes of treatment with mechanical thrombectomy (MT) in patients with CKD seem to be poorer than in the general population. Long-term follow-up studies are lacking.

Objectives: Assessing short- and long-term outcomes (up to 365 days after stroke) in MT-treated AIS patients with concomitant CKD.

Patients and methods: The study included all AIS patients treated with MT in a Comprehensive Stroke Center from 2019 to 2021. The subjects were divided into CKD group (best glomerular filtration rate during hospitalization <60 ml/min/1.73 m2 or CKD diagnosed in patient’s medical history) and controls. In-hospital, 90-day and 365-day mortality and rate of good functional outcomes (defined as modified Rankin Scale ≤2) were compared between CKD patients and controls as well as between patients with CKD stages 1-3 (GFR ≥30ml/min/1.73m2) and 4-5 (GFR <30ml/min/1.73m2). Factors associated with abovementioned outcomes were identified using univariable logistic regression analyses and then added to multivariable analyses.

Results: CKD patients had higher 90- and 365-day mortality and lower 90- and 365-day good functional outcome rates than controls. Patients with CKD stage 4-5 had significantly higher in-hospital, 90-day and 365-day mortality than patients with CKD stage 1-3. Neither CKD nor its late stages (4-5) were independently associated with short- and long-term mortality and functional outcomes of MT.

Conclusions: Outcomes of MT-treatment in CKD patients are worse, especially in advanced stages of the disease, but CKD is not independently associated with bad prognosis. CKD alone should not be a contraindication for MT in otherwise eligible patients, although patients with impaired kidney function require more careful postprocedural monitoring.

Full-text article available only as a pdf file for download

Download article